Background: CDK4/6 inhibitors are the new standard of care in hormonal receptors positive (HR+) advanced breast cancer (ABC). Phase III trials demonstrated an improvement in survival outcomes in patients with combined endocrine approach compared to endocrine therapy (ET) alone. The aim of this retrospective study was to assess prognostic factors for clinical response to CDK4/6 inhibitors. Methods: All patients receiving CDK4/6 inhibitors from September 2016 to July 2019 were registered in a database. Data on tumor and patient’s characteristics as well as concomitant medications were collected. Survival data were analyzed by Kaplan Meier curves and log rank test. Treatment toxicities were graded according to CTCAE v5. A drug-drug inte...
20Background: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors + endocrine therapy (ET) prolonge...
BACKGROUND: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is...
Background To compare the efficacy and toxicity of the combination of cyclin-dependent kinase 4/6...
Background: CDK4/6 inhibitors are the new standard of care in hormonal receptors positive (HR+) adva...
BACKGROUND: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is...
Background: Breast cancer (BC) is one of the leading causes of cancer-related deaths worldwide. Stan...
Background: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is...
Abstract Background Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine th...
Background: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is...
Background: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is...
Background: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is...
Background: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is...
Objective: The objective of this selective EBM review is to determine whether or not CDK 4/6 inhibit...
Objective: The objective of this selective EBM review is to determine whether or not CDK 4/6 inhibit...
Objective: The objective of this selective EBM review is to determine whether or not CDK 4/6 inhibit...
20Background: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors + endocrine therapy (ET) prolonge...
BACKGROUND: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is...
Background To compare the efficacy and toxicity of the combination of cyclin-dependent kinase 4/6...
Background: CDK4/6 inhibitors are the new standard of care in hormonal receptors positive (HR+) adva...
BACKGROUND: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is...
Background: Breast cancer (BC) is one of the leading causes of cancer-related deaths worldwide. Stan...
Background: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is...
Abstract Background Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine th...
Background: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is...
Background: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is...
Background: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is...
Background: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is...
Objective: The objective of this selective EBM review is to determine whether or not CDK 4/6 inhibit...
Objective: The objective of this selective EBM review is to determine whether or not CDK 4/6 inhibit...
Objective: The objective of this selective EBM review is to determine whether or not CDK 4/6 inhibit...
20Background: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors + endocrine therapy (ET) prolonge...
BACKGROUND: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is...
Background To compare the efficacy and toxicity of the combination of cyclin-dependent kinase 4/6...